Reversible alopecia in Vogt-Koyanagi-Harada disease and sympathetic ophthalmia

详细信息    查看全文

• 作者：Chiu-Tung Chuang (1)
  Po-Sian Huang (1)
  Shih-Chou Chen (1)
  Shwu-Jiuan Sheu (1) (2)
  
• 刊名：Journal of Ophthalmic Inflammation and Infection
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：3
• 期：1
• 全文大小：432KB
• 参考文献：1. Rao NA: Mechanisms of inflammatory response in sympathetic ophthalmia and VKH syndrome. / Eye 1997, 11:213鈥?16. CrossRef
  2. Ohno S, Minakawa R, Matsuda H: Clinical studies of Vogt-Koyanagi-Harada鈥檚 disease. / Jpn J Ophthalmol 1988, 32:334鈥?43.
  3. Arevalo JF, Garcia RA, Al-Dhibi HA, Sanchez JG, Suarez-Tata L: Update on sympathetic ophthalmia. / Middle East Afr J Ophthalmol 2012, 19:13鈥?1. CrossRef
  4. Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, Pivetti-Pezzi P, Tessler HH, Usui M: Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. / Am J Ophthalmol 2001, 131:647鈥?52. CrossRef
  5. Chee SP, Jap A, Bacsal K: Spectrum of Vogt-Koyanagi-Harada disease in Singapore. / Int Ophthalmol 2007, 27:137鈥?42. CrossRef
  6. Galor A, Davis JL, Flynn HW Jr, Feuer WJ, Dubovy SR, Setlur V, Kesen MR, Goldstein DA, Tessler HH, Ganelis IB, Jabs DA, Thorne JE: Sympathetic ophthalmia: incidence of ocular complications and vision loss in the sympathizing eye. / Am J Ophthalmol 2009, 148:704鈥?10. CrossRef
  7. Read RW, Yu F, Accorinti M, Bodaghi B, Chee SP, Fardeau C, Goto H, Holland GN, Kawashima H, Kojima E, Lehoang P, Lemaitre C, Okada AA, Pivetti-Pezzi P, Secchi A, See RF, Tabbara KF, Usui M, Rao NA: Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. / Am J Ophthalmol 2006, 142:119鈥?24. CrossRef
  8. Lai TYY, Chan RPS, Chan CKM, Lam DS: Effects of duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. / Eye 2009, 23:543鈥?48. CrossRef
  9. Kawaguchi T, Horie S, Bouchenaki N, Ohno-Matsui K, Mochizuki M, Herbort CP: Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease. / Int Ophthalmol 2010, 30:41鈥?0. CrossRef
  10. Yang P, Ren Y, Li B, Fang W, Meng Q, Kijlstra A: Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. / Ophthalmol 2007, 114:606鈥?14. CrossRef
  11. Sheu SJ, Kou HK, Chen JF: Significant prognostic factors for Vogt-Koyanagi-Harada disease in the early stage. / Kaohsiung J Med Sci 2004, 20:97鈥?05. CrossRef
  12. Abad S, Monnet D, Caillat-Zucman S, Mrejen S, Blanche P, Chalumeau M, Mouthon L, Dhote R, Br茅zin AP: Characteristics of Vogt-Koyanagi-Harada disease in a French cohort: ethnicity, systemic manifestations, and HLA genotype data. / Ocul Immunol Inflam 2008, 16:3鈥?. CrossRef
  13. Mondkar SV, Biswas J, Ganesh SK: Analysis of 87 cases with Vogt-Koyanagi-Harada disease. / Jpn J Ophthalmol 2000, 44:296鈥?01. CrossRef
  14. Sheu SJ, Kou HK, Chen JF: Prognostic factors for Vogt-Koyanagi-Harada disease. / J Chin Med Assoc 2003, 66:148鈥?54.
  15. Keino H, Goto H, Usui M: Sunset glow fundus in Vogt-Koyanagi-Harada disease with or without chronic ocular inflammation. / Graefae Arch Clin Exp Ophthalmol 2002, 40:878鈥?82. CrossRef
  16. Ondrey FG, Moldestad E, Mastoianni MA, Pikus A, Sklare D, Vernon E, Nusenblatt R, Smith J: Sensorineural hearing loss in Vogt-Koyanagi-Harada syndrome. / Laryngoscope 2006, 116:1873鈥?876. CrossRef
  
• 作者单位：Chiu-Tung Chuang (1)
  Po-Sian Huang (1)
  Shih-Chou Chen (1)
  Shwu-Jiuan Sheu (1) (2)
  
  1. Department of Ophthalmology, Kaohsiung Veterans General Hospital, 386, Ta-Chung 1st Road, Kaohsiung, 813, Taiwan
  2. School of Medicine, National Yang-Ming University, Taipei, 112, Taiwan
  

文摘

Background Vogt-Koyanagi-Harada (VKH) disease and sympathetic ophthalmia (SO) are both autoimmune disorders targeting melanin-bearing cells, even though their etiologies are different. Both shared many ocular and systemic manifestations, including integumentary findings. Most of the literature focused on the ocular manifestations and related treatment. Alopecia was seldom mentioned. Findings We report one case of VKH disease and one case of SO. Both developed severe alopecia and early sunset glow fundus, which are probably due to incomplete treatment. Fortunately, the alopecia improved soon after systemic steroid treatment. Conclusions Early and complete treatments are important in the management of VKH or SO and prevent integumentary manifestation. Alopecia can be reversible after steroid treatment in time.